menu

Quintiles Library

Show Filters
Video
Global approaches to post-approval safety are changing rapidly around the world. With a much greater interest in watching the performance of new drugs and devices once they come to market. If you are thinking about bringing a new drug or medical device to the market in Europe, you need to know what regulators are expecting, in particular since the new pharmacovigilance...
White Paper
Hospital mergers and acquisitions, group purchasing organizations (GPOs), integrated delivery networks (IDNs), accountable care organizations (ACOs) and value-added committees (VACs) have changed the sales engagement strategies of medical device and diagnostics companies. Learn how continued advances in data and analytics can help: • Identify new markets based on timely...
Explore More
Case Study
Emory Healthcare wanted to improve physician referral rates in a cost effective manner. That meant reaching out to expand its business with physicians who were already referring 30%-70% of their patients. But it didn’t have access to the necessary referral data. Learn how QuintilesIMS helped Emory Healthcare.
Read More
White Paper
Global regulatory agencies have licensed vaccines to prevent at least 25 infectious diseases. Historically, however, new vaccines typically became available in low- and middle-income countries years (often decades) after being introduced in high-income countries. More recent initiatives have narrowed this inequity, with well-documented positive impacts on health and...
Explore More
White Paper
Asia is on the rise in medical technology development and sales. This paper examines opportunities for medtech in Asia, common pitfalls and how to avoid them, and the use of strategic outsourcing to realize greater value and mitigate risks.
Explore More
White Paper
This QuintilesIMS White Paper provides a comprehensive scientific review of Phase I trials in oncology, and highlights best practices and operational recommendations for their successful delivery. Early-phase studies, which introduce an investigational new drug into human subjects, represent a challenging first step in a new drug’s clinical development program. They are...
Explore More
Brochure
With new European medical device regulations on the horizon, including increased Notified Body involvement and heightened market surveillance, manufacturers face additional challenges to maintaining product CE Marking and bringing products to market.
Read More
Fact Sheet
When seeking to increase asset value in early clinical development or protect commercial interests, you need efficient and trusted cardiac safety services. Access actionable insights faster with QuintilesIMS’s powerful combination of centralized ECG monitoring and clinical expertise.
Read More
Presentation
With increasing pricing pressures in a therapeutic area which has seen many recent drug approvals, diabetes drug developers are seeking to enhance their clinical development and portfolio. By leveraging Continuous Glucose Monitoring (CGM), sponsors conducting trials in diabetes as well as other indications have the potential to enhance patient safety, accelerate clinical...
Explore More
Presentation
Coverage and reimbursement of new treatments for orphan diseases will become increasingly restrictive in the years to come. In this webinar, our experts offer strategies on ways to meet the challenges to market access in a time of increased pushback from patients, payers and regulators.
Explore More
Presentation
While privacy is the responsibility of all healthcare organizations, life-science companies and real-world evidence (RWE) leaders are driving and benefiting from the implementation of new global privacy standards in the health data sharing space. Leading companies are building dedicated RWE evidence platforms in specific disease areas that extend across multiple countries...
Explore More
Presentation
A presentation given at the iCAN Summit 2017 answers questions about how we can improve the care of children. Here’s what's being asked: Who is doing the research? Overview of basic industry sponsored research and the different entities involved Why we care about pediatric trials? The facts and regulations How can we help improve care for children? Pediatric...
Explore More
Presentation
In this webinar, we’ll outline how QuintilesIMS’ Forecasting Platform can be used to perform many different types of variability analysis. We’ll look at the tradeoffs between traditional scenario-based planning – where planners have a number of self-contained plans that aggregate various contingencies – and more sophisticated Monte-Carlo and event-driven variability...
Explore More
Video
Are you trying to understand the strategic landscape, utilize data to optimize asset and enterprise value, and secure funding to get to your next milestone?  With personalized attention and global therapeutic expertise informed by in-depth real-world analytics, QuintilesIMS can meet emerging biopharma companies where you are with solutions tailored to your needs. From...
White Paper
Alzheimer’s Disease continues to be a common cause of death in elderly patients. To successfully address five critical challenges in this therapy area, pharma and biotech must adopt an 'act now' mentality, working together to make headway against this complex disease.
Explore More
White Paper
Increasing leverage of electronic health records (EHRs), imaging systems and social media is delivering groundbreaking patient-centric insight. However, as companies seek deeper understanding of health outcomes via patient-level data, privacy-enhancing capabilities are becoming a critical source of leadership – and key to unlocking the full value of real-world evidence...
Explore More
Infographic
QuintilesIMS takes oncology expertise to a new level. With meaningful insights based on the world’s largest curated healthcare data source and advanced analytics. You’ll discover ways to improve clinical trials. More robust evidence to support treatments. A clearer picture of the patient journey. And insights that actually lead to better commercial performance.
Read More
Presentation
As if patient identification and engagement weren’t challenging enough, add in a rare disease study, and it can feel like a daunting process. Patient populations are small and widely dispersed around the globe, and finding the proper sites to support these patients is difficult. As an emerging biopharma company, limited resources can make these challenges that much...
Explore More
Fact Sheet
Risk-based monitoring (RBM) continues to transform clinical development using data insights delivered by innovative technology, enhanced processes and new roles to optimize execution. Biopharma is adopting RBM as the standard execution model for their studies. QuintilesIMS is leading this evolution with an expanded RBM offering, Centralized Monitoring. Learn more about...
Read More